Natural history, predictive factors of apparent disease (structural or biochemical) and spontaneous excellent response in patients with papillary thyroid carcinoma and indeterminate response to initial therapy with radioiodine

[1] Haugen BR(2016)American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer Thyroid 26 1-133

[2] Alexander EK(2010)Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system Thyroid 20 1341-9

[3] Bible KC(2013)Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma Eur. J. Endocrinol. 170 23-30

[4] Tuttle RM(2016)Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients Endocrine 54 467-75

[5] Tala H(2017)Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations J. Clin. Endocrinol. Metab. 102 1757-64

[6] Shah J(2019)Individualized follow-up strategy for patients with an indeterminate response to initial therapy for papillary thyroid carcinoma Thyroid 29 209-15

[7] Jeon MJ(2019)Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend J. Endocrinol. Investig. 42 1223-30

[8] Kim WG(2021)Thyroglobulin antibodies as a prognostic factor in papillary thyroid carcinoma patients with indeterminate response after initial therapy Horm. Metab. Res. 53 94-9

[9] Park WR(2021)Natural course of the American Thyroid Association response to therapy statuses (dynamic risk stratification) in differentiated thyroid cancer Eur. Thyroid J. 10 198-207

[10] Lamartina L(2017)High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas Eur. J. Endocrinol. 176 497-504

[1] Haugen BR(2016)American thyroid association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer Thyroid 26 1-133

[2] Alexander EK(2010)Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system Thyroid 20 1341-9

[3] Bible KC(2013)Modified dynamic risk stratification for predicting recurrence using the response to initial therapy in patients with differentiated thyroid carcinoma Eur. J. Endocrinol. 170 23-30

[4] Tuttle RM(2016)Papillary thyroid carcinomas with biochemical incomplete or indeterminate responses to initial treatment: repeat stimulated thyroglobulin assay to identify disease-free patients Endocrine 54 467-75

[5] Tala H(2017)Refining dynamic risk stratification and prognostic groups for differentiated thyroid cancer with TERT promoter mutations J. Clin. Endocrinol. Metab. 102 1757-64

[6] Shah J(2019)Individualized follow-up strategy for patients with an indeterminate response to initial therapy for papillary thyroid carcinoma Thyroid 29 209-15

[7] Jeon MJ(2019)Surveillance of patients with differentiated thyroid cancer and indeterminate response: a longitudinal study on basal thyroglobulin trend J. Endocrinol. Investig. 42 1223-30

[8] Kim WG(2021)Thyroglobulin antibodies as a prognostic factor in papillary thyroid carcinoma patients with indeterminate response after initial therapy Horm. Metab. Res. 53 94-9

[9] Park WR(2021)Natural course of the American Thyroid Association response to therapy statuses (dynamic risk stratification) in differentiated thyroid cancer Eur. Thyroid J. 10 198-207

[10] Lamartina L(2017)High-sensitive basal serum thyroglobulin 6-12 months after thyroid ablation is strongly associated with early response to therapy and event-free survival in patients with low-to-intermediate risk differentiated thyroid carcinomas Eur. J. Endocrinol. 176 497-504